ATE536864T1 - Metoprololsuccinat tabletten mit verlängerter freisetzung und verfahren für deren herstellung - Google Patents

Metoprololsuccinat tabletten mit verlängerter freisetzung und verfahren für deren herstellung

Info

Publication number
ATE536864T1
ATE536864T1 AT06252598T AT06252598T ATE536864T1 AT E536864 T1 ATE536864 T1 AT E536864T1 AT 06252598 T AT06252598 T AT 06252598T AT 06252598 T AT06252598 T AT 06252598T AT E536864 T1 ATE536864 T1 AT E536864T1
Authority
AT
Austria
Prior art keywords
extended release
production
metoprolol succinate
release tablets
succinate extended
Prior art date
Application number
AT06252598T
Other languages
English (en)
Inventor
Tomer Gold
Nava Shterman
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Application granted granted Critical
Publication of ATE536864T1 publication Critical patent/ATE536864T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AT06252598T 2006-02-24 2006-05-18 Metoprololsuccinat tabletten mit verlängerter freisetzung und verfahren für deren herstellung ATE536864T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77670606P 2006-02-24 2006-02-24

Publications (1)

Publication Number Publication Date
ATE536864T1 true ATE536864T1 (de) 2011-12-15

Family

ID=36928616

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06252598T ATE536864T1 (de) 2006-02-24 2006-05-18 Metoprololsuccinat tabletten mit verlängerter freisetzung und verfahren für deren herstellung

Country Status (13)

Country Link
US (1) US20070202172A1 (de)
EP (1) EP1842534B1 (de)
JP (1) JP2009527554A (de)
KR (1) KR20080099334A (de)
CN (1) CN101516356A (de)
AT (1) ATE536864T1 (de)
BR (1) BRPI0621397A2 (de)
CA (1) CA2642340A1 (de)
IL (1) IL193357A0 (de)
MX (1) MX2008010877A (de)
PL (1) PL1842534T3 (de)
RU (1) RU2008136766A (de)
WO (1) WO2007097770A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA98449C2 (en) 2005-12-13 2012-05-25 Инсайт Корпорейшин Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
DE102008047910A1 (de) * 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
FR2936709B1 (fr) * 2008-10-02 2012-05-11 Ethypharm Sa Comprimes alcoolo-resistants.
DK2255791T3 (da) * 2009-04-03 2012-03-05 Zaklady Farmaceutyczne Polpharma Sa Forlænget-frigivelse-farmaceutisk sammensætning omfattende metoprololsuccinat
CN102008457B (zh) * 2009-09-04 2014-04-02 北京天衡药物研究院 酒石酸美托洛尔骨架缓释片
EP2521570A4 (de) * 2009-12-29 2015-05-13 Impax Laboratories Inc Feste gastroretentive orale dosierungsformen mit quellfähigem hydrophilem polymer
CN101773482B (zh) * 2009-12-30 2012-04-25 中国科学院上海药物研究所 一种三段式脉冲释药控释片及其制备方法
AU2011224484A1 (en) 2010-03-10 2012-09-27 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
AR086983A1 (es) 2011-06-20 2014-02-05 Incyte Corp Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
CN103655480B (zh) * 2012-09-14 2016-12-21 中国人民解放军军事医学科学院毒物药物研究所 一种美托洛尔的缓释药物及其制备方法
MY191357A (en) 2012-11-15 2022-06-19 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
PT3030227T (pt) 2013-08-07 2020-06-25 Incyte Corp Formas de dosagem de libertação prolongada para um inibidor de jak1
PT3265126T (pt) * 2015-03-03 2021-08-30 Saniona As Formulação combinada de tesofensina e metoprolol
EP3428184A1 (de) * 2017-07-09 2019-01-16 Universitätsklinikum Hamburg-Eppendorf Mittel zur behandlung von herz-kreislauf-erkrankung
US10744087B2 (en) 2018-03-22 2020-08-18 Incarda Therapeutics, Inc. Method to slow ventricular rate
CN111419813A (zh) * 2020-05-09 2020-07-17 深圳市道科思医药有限公司 一种琥珀酸美托洛尔的缓释片剂及其制备方法
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2022074681A1 (en) * 2020-10-08 2022-04-14 Harman Finochem Limited Pharmaceutical compositions with enhanced blend uniformity and content uniformity

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8518301D0 (en) * 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
SE450087B (sv) * 1985-10-11 1987-06-09 Haessle Ab Korn med kontrollerad frisettning av farmaceutiskt aktiva emnen som anbringats teckande pa ett kompakt olosligt kernmaterial
US5246714A (en) * 1985-10-11 1993-09-21 Aktiebolaget Hassle Drug preparation
SE455836B (sv) * 1985-10-11 1988-08-15 Haessle Ab Beredning med kontrollerad frisettning innehallande ett salt av metoprolol samt metod for framstellning av denna beredning
JPH0819003B2 (ja) * 1988-09-27 1996-02-28 武田薬品工業株式会社 有核顆粒およびその製造法
JP3453186B2 (ja) * 1994-04-14 2003-10-06 共和薬品工業株式会社 徐放性マイクロカプセルおよびその製造方法
SE9402422D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New beads for controlled release and a pharmaceutical preparation containing the same
SE9803871D0 (sv) * 1998-11-11 1998-11-11 Pharmacia & Upjohn Ab Therapeutic method and formulation
US9358214B2 (en) * 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US7022342B2 (en) * 2002-03-28 2006-04-04 Andrx Corporation, Inc. Controlled release oral dosage form of beta-adrenergic blocking agents
US7314640B2 (en) * 2003-07-11 2008-01-01 Mongkol Sriwongjanya Formulation and process for drug loaded cores
ATE549015T1 (de) * 2003-10-31 2012-03-15 Hexal Ag Pharmazeutische wirkstoffhaltige formulierung mit überzug
DE10353186A1 (de) * 2003-11-13 2005-06-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform, enthaltend eine in Bezug auf die Wirkstoffabgabe modulatorisch wirkende Substanz
WO2005084636A2 (en) * 2004-02-27 2005-09-15 Ranbaxy Laboratories Limited A process for the preparation of controlled-release pharmaceutical composition of metoprolol
US20060204575A1 (en) * 2005-03-11 2006-09-14 Hengsheng Feng Amphetamine formulations

Also Published As

Publication number Publication date
KR20080099334A (ko) 2008-11-12
EP1842534A1 (de) 2007-10-10
IL193357A0 (en) 2009-05-04
WO2007097770A1 (en) 2007-08-30
BRPI0621397A2 (pt) 2012-04-17
CA2642340A1 (en) 2007-08-30
JP2009527554A (ja) 2009-07-30
CN101516356A (zh) 2009-08-26
US20070202172A1 (en) 2007-08-30
PL1842534T3 (pl) 2012-05-31
EP1842534B1 (de) 2011-12-14
MX2008010877A (es) 2008-11-25
WO2007097770A8 (en) 2007-12-06
RU2008136766A (ru) 2010-03-27

Similar Documents

Publication Publication Date Title
ATE536864T1 (de) Metoprololsuccinat tabletten mit verlängerter freisetzung und verfahren für deren herstellung
ATE556074T1 (de) Neue imidazoä1,5-aüpyridinderivate, verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die diese enthalten
CR20110579A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750
PH12013502192A1 (en) Antibodies against human angiopoietin 2
ATE482194T1 (de) Indolonderivate, verfahren zu deren herstellung und deren anwendungen
ECSP066376A (es) FORMA CRISTALINA GAMMA-d DEL CLORHIDRATO DE IVABRADINA, SU PROCEDIMIENTO DE PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LA CONTIENEN
AR053147A1 (es) Forma cristalina del clorhidrato de ivabradina, un procedimiento para su preparacion y composiciones farmaceuticas que la contienen
CL2007003627A1 (es) Compuestos derivados de 3-h-pirazolopiridinas; metodo de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades de crecimiento vascular desregulado tal como leucemia mielogena aguda, retinopatia, artritis reumatoide, psorias
ATE460401T1 (de) 1,2,4,5-tetrahydro-3h-benzazepinderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
UY31524A1 (es) Nuevos compuestos 010
UY29839A1 (es) Ácidos fenoxiaceticos sustituidos, composiciones farmacéuticas conteniéndolos, procesos para su preparación y aplicaciones.
EA200900282A1 (ru) Применение полиолов для получения устойчивых полиморфных форм рифаксимина
UY29223A1 (es) Ácidos fenoxiacéticos sustituidos, composiciones farmacéuticas que los contienen y procesos para su preparación
IN2012DN01531A (de)
ATE502024T1 (de) Diosmetin-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
ATE413875T1 (de) Zusammensetzungen enthaltend levetiracetam und verfahren zu deren herstellung.
ATE425961T1 (de) Salze substituierter allophansaureester und deren verwendung in arzneimitteln
MA31445B1 (fr) Composition à libération modifiée comprenant un dérivé de somatostatine en microparticules
TW200718698A (en) Process for preparing new tiotropium salts, new tiotropium salts as such and pharmaceutical compositions thereof
ATE500226T1 (de) Aripiprazolhemifumarat und verfahren zu dessen herstellung
MX2009008221A (es) Antagonista de receptor de cromeno s1p1.
ATE517900T1 (de) Heptarylen-und octarylentetracarbonsäurediimide und deren herstellung
CO6390054A2 (es) Formas cristalinas de un compuesto 3-carboxipropil-aminotetralina
MX2009012929A (es) Compuestos organicos.
BRPI0810871A2 (pt) Composto, processo de preparação de um composto, composição farmacêutica e utilização de um composto.